在3D瘤微环境中,CLL和ALL衍生的CAR T细胞之间的功能差异突出显示了CXCR4和IL-10作为潜在的调节标
Janin Dingfelder1,2,3, Michael Aigner1,2,3, Jana Lindacher1,2,3
1Department of Internal Medicine 5, Hematology and Oncology Universitätsklinikum Erlangen Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) Erlangen Germany.
HemaSphere
|December 10, 2025
概括
化学抗原受体 (CAR) T细胞疗法在慢性淋巴细胞白血病 (CLL) 中由于T细胞耗尽和免疫抑制瘤微环境 (TME) 的作用,显示出有限的疗效. 针对TME的组合疗法在改善CLL中CAR T细胞功能方面表现有前途.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞疗法细胞疗法
背景情况:
- 尽管有针对性的疗法,慢性淋巴细胞白血病 (CLL) 的治疗仍然具有挑战性.
- 化学抗原受体 (CAR) T细胞疗法对急性淋巴细胞白血病 (ALL) 有效,但对CLL效果较差.
- 假设CAR T细胞耗尽和免疫抑制瘤微环境 (TME) 限制了CLL的疗效.
研究的目的:
- 在3DTME共同培养模型中研究CLL中的CAR T细胞功能.
- 为了比较CAR T细胞在CLL中的表现与ALL患者.
- 确定新的组合策略,以增强对CLL的CAR T细胞疗法.
主要方法:
- 使用了一个自的3D TME共同培养模型.
- 从CLL和ALL患者获得的CAR T细胞进行比较.
- 评估了CAR T细胞耗尽和细胞毒性.
- 评估的组合疗法包括IL-10或CXCR4阻断.
主要成果:
- 与ALL患者相比,来自CLL患者的CAR T细胞表现出增加的疲劳和减少的细胞毒性.
- 与IL-10或CXCR4阻断的联合治疗改善了对CLL细胞的CAR T细胞细胞毒性.
- 在3D模型中,即使在受 stromal 保护的区域,也观察到更高的疗效.
结论:
- 在CLL中,CAR T细胞功能障碍与T细胞耗尽和TME有关.
- 针对TME的组合策略,如IL-10或CXCR4阻断,可以增强对CLL的CAR T细胞治疗.
- 这些发现支持开发新的治疗方法,以改善CLL治疗结果.
相关概念视频
T Cell Activation and Clonal Selection
14.6K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.6K
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K


